XOMA Royalty (NASDAQ:XOMA) Shares Cross Above 200-Day Moving Average - Here's What Happened

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $24.27 and traded as high as $27.06. XOMA Royalty shares last traded at $26.30, with a volume of 20,669 shares traded.

Wall Street Analysts Forecast Growth

XOMA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $104.00 price target on shares of XOMA Royalty in a research note on Wednesday, May 28th. Benchmark assumed coverage on XOMA Royalty in a research note on Thursday, April 17th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Wall Street Zen downgraded XOMA Royalty from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th.

XOMA Royalty Price Performance

The stock has a 50 day moving average price of $25.82 and a two-hundred day moving average price of $24.24. The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54. The company has a market capitalization of $305.00 million, a PE ratio of -22.16 and a beta of 0.93.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.32. The company had revenue of $15.91 million during the quarter, compared to analysts' expectations of $6.75 million. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. Equities analysts forecast that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.

Insider Activity at XOMA Royalty

In other XOMA Royalty news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the completion of the sale, the insider directly owned 1,267,545 shares in the company, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Owen Hughes sold 25,637 shares of XOMA Royalty stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total value of $650,667.06. Following the completion of the transaction, the chief executive officer owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This trade represents a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.20% of the company's stock.

Institutional Investors Weigh In On XOMA Royalty

A number of large investors have recently bought and sold shares of the business. Woodline Partners LP boosted its holdings in XOMA Royalty by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock valued at $3,359,000 after purchasing an additional 12,284 shares during the period. Stonepine Capital Management LLC grew its holdings in XOMA Royalty by 3.3% during the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock worth $2,587,000 after acquiring an additional 4,113 shares during the last quarter. Eversept Partners LP grew its holdings in XOMA Royalty by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after acquiring an additional 1,128 shares during the last quarter. Northern Trust Corp boosted its stake in shares of XOMA Royalty by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after purchasing an additional 1,340 shares during the last quarter. Finally, CM Management LLC boosted its stake in shares of XOMA Royalty by 16.4% in the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after purchasing an additional 9,000 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.